Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 90.1%

Neg 90.1% Neu 0% Pos 0%

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.